Study Results for GW Pharma’s Epidolex

Photo Credit: Pixabay

Photo Credit: Pixabay

In the first of four phase III clinical studies surrounding the cannabis-based epilepsy medication Epidiolex, the manufacturer GW Pharmaceuticals revealed its medication successfully treated a severe form of epilepsy in children. The study involving 120 children found Epidiolex syrup was able to reduce the monthly number of seizures for kids suffering from Dravet's Syndrome by 39%, while the placebo only reduced the seizures by 13%. GW Pharmaceuticals will now seek regulatory approval from the USFDA.

This information has been brought to you by the Marijuana Business Daily and approved by our Chief Medical Officer.